A study on anti-tumor T lymphocytes opens up future therapeutic products for patients with acute myeloid leukemia
![A study on anti-tumor T lymphocytes opens up future therapeutic products for patients with acute myeloid leukemia](/images/news/2024/a-study-on-anti-tumor-t-lymphocytes-opens-up-future-therapeutic-products-for-patients-with-acute-myeloid-leukemia.jpg)
Data publicării: 05-02-2024
Actualizare la: 21-05-2024
Subiect: Cercetare
Durată de citire estimată: 1 min.
A team of researchers from IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, led by Professor Chiara Bonini, Full Professor of UniSR Hematology and Group leader of the Unit of Experimental Immunology, demonstrated how anti-tumor T lymphocytes can be identified, monitored over time and characterized in patients with acute myeloid leukemia and how they can exploit inhibition mechanisms put in place by the tumor to escape recognition by our immune system.
The ultimate goal of the research project is to identify new reagents that could lead to the development of therapeutic products for patients with acute myeloid leukemia.
The study was recently published in the prestigious journal Science Advances.
研究项目
通过对造血干细胞移植后患者外周血中的抗肿瘤T淋巴细胞进行详细研究,研究人员观察到,这些细胞存在于90%的被分析患者体内,但不幸的是,尽管前提条件如此优越,它们却无法在免疫系统中发挥 "杀手 "的功能。
“原因在于这些抗肿瘤受体会出现 "功能耗竭",这是因为它们的表面存在可以 "关闭它们 "的分子,这种现象似乎与疾病复发的患者特别相关,”该研究的第一作者、实验血液学组的研究员Francesco Manfredi医生说。
该研究的共同第二作者、实验血液学组研究员Eliana Ruggiero医生补充说: "通过将抗肿瘤T淋巴细胞上表达的蛋白质的详细分析与转录组和肽链测序技术(后者是与赫尔辛基大学的Vincenzo Cerullo教授合作进行的)相结合,我们不仅发现了一个TCR库,即T淋巴细胞表面表达的能够识别肿瘤的蛋白质,而且还发现了肿瘤细胞表达的分子,这些分子将来可以作为新的治疗靶点"。
研究人员利用CRISPR/Cas9技术制造的 "分子剪刀",可以 "剪切 "和删除特定的相关基因,然后生成肿瘤特异性T淋巴细胞 "大军",将识别出的抗肿瘤TCR插入细胞中。
未来展望
Chiara Bonini医生指出:"这项研究为治疗急性髓性白血病患者带来了新希望。通过利用所研究的几乎所有患者体内都存在抗肿瘤 T 淋巴细胞以及这些细胞无法识别肿瘤的特点,我们一直在努力寻找新的试剂,以便在未来用于扩大该病患者的治疗选择范围"。